Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes
28 Juin 2013 - 10:30PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a
biopharmaceutical company focused on developing and commercializing
an inhaled anti-infective to treat patients battling serious lung
diseases that are often life-threatening, today announced that it
was included on the list of companies to join the broad-market
Russell Global® and the Russell 3000® Indexes when Russell
Investments reconstitutes its comprehensive set of U.S. and global
equity indexes on June 28, 2013 www.russell.com/indexes.
Annual reconstitution of Russell's U.S. indexes captures the
4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. Membership in the Russell 3000, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell 2000® Index as
well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Approximately $4.1
trillion in assets are benchmarked to the Russell Indexes. Russell
calculates more than 700,000 benchmarks daily covering
approximately 98 percent of the investable market globally, more
than 80 countries and 10,000 securities. These investment tools
originated from Russell's multi-manager investment business in the
early 1980s when the company saw the need for a more objective,
market-driven set of benchmarks in order to evaluate outside
investment managers.
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offers actively managed multi-asset
portfolios and services that include advice, investments and
implementation. Russell stands with institutional investors,
financial advisors and individuals working with their advisors --
using the firm's core capabilities that extend across capital
market insights, manager research, portfolio construction,
portfolio implementation and indexes to help each achieve their
desired investment outcomes.
Russell has more than $173 billion in assets under management
(as of 3/31/2013) and works with over 2,500 institutional clients,
independent distribution partners and individual investors
globally. As a consultant to some of the largest pools of capital
in the world, Russell has $2.6 trillion in assets under advisement
(as of 12/31/2012). It has four decades of experience researching
and selecting investment managers and meets annually with more than
2,200 managers around the world. Russell traded more than $1.4
trillion in 2012 through its implementation services business.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE®, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections and patients
with non-tuberculous mycobacteria (NTM) lung infections. For more
information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements that are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of results of preclinical studies and clinical trials and
preclinical and clinical data and the anticipated benefits of
Insmed's products, and to the Company's cash position and financing
needs, constitute forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. Such risks and
uncertainties include, without limitation, failure or delay of U.S.
Food and Drug Administration and other regulatory reviews and
approvals, competitive developments affecting the Company's product
candidates, delays in product development or clinical trials or
other studies, patent disputes and other intellectual property
developments relating to the Company's product candidates,
unexpected regulatory actions, delays or requests, the failure of
clinical trials or other studies or results of clinical trials or
other studies that do not meet expectations, inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations.
Investor Relations Contacts: LHA Anne Marie Fields Senior
Vice President 212-838-3777 afields@lhai.com Bruce Voss Managing
Director 310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024